Injectable hydroxocobalamin vials recalled due to sterility concerns
Pharmacy Innovations is recalling hydroxocobalamin-PF injectable vials (1mg/ml) distributed nationwide because FDA inspection found insanitary conditions at the manufacturing facility that could compromise product sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for lack of sterility assurance at the manufacturing facility. No illnesses or injuries have been reported, but non-sterile injectable medications pose a significant risk of infection, meeting the rubric criterion of risk-of-harm products where injury has not yet been reported.
Plain-English summary
Pharmacy Innovations is recalling hydroxocobalamin-PF injectable solution (1mg/ml in 1ml vials) that was distributed nationwide. The product is a prescription-only injectable medication.
The recall was issued after an FDA inspection discovered insanitary conditions at the manufacturing facility. These conditions resulted in a lack of assurance that the product maintained sterility during manufacturing, which is critical for injectable medications.
Healthcare providers and patients who have received this medication should contact their healthcare provider to discuss any concerns. Facilities or individuals with affected vials should discontinue use and contact their pharmacy or healthcare provider for guidance on proper product disposal and alternative treatment options.
The recalled product
- Product
- HYDROXOCOBALAMIN-PF- 1MG/ML (1ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Injectable
- Hazard
- contamination
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221116@36 t20221117@11 t20221111@61
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27